Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 19/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602196 | 0.90 | NPY2R (0.80) | NPY2R | |
| SCHEMBL7607274 | 0.90 | NPY2R (0.80) | NPY2R | |
| SCHEMBL14537895 | 0.90 | NPY2R (0.80) | NPY2R | |
| SCHEMBL7603845 | 0.89 | NPY2R (0.82) | NPY2R | |
| SCHEMBL7599257 | 0.88 | NPY2R (1.00) | NPY2R | |
| SCHEMBL7600410 | 0.87 | NPY2R (0.79) | NPY2R | |
| SCHEMBL7604107 | 0.87 | NPY2R (0.79) | NPY2R | |
| SCHEMBL7602805 | 0.86 | NPY2R (0.97) | NPY2R | |
| SCHEMBL7607333 | 0.83 | NPY2R (0.68) | NPY2R | |
| SCHEMBL7603844 | 0.81 | NPY2R (0.81) | NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | NPY2R 1/4885KDM4E 1365/4885MEN1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.